Immuneering Corp. (IMRX)
3.495
+0.04
(+1.01%)
USD |
NASDAQ |
Nov 18, 16:00
3.495
0.00 (0.00%)
After-Hours: 19:42
Immuneering Enterprise Value : 82.21M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 82.21M |
| November 16, 2026 | 86.10M |
| November 13, 2026 | 98.40M |
| November 12, 2026 | 95.81M |
| November 11, 2026 | 103.58M |
| November 10, 2026 | 107.47M |
| November 09, 2026 | 94.51M |
| November 06, 2026 | 96.46M |
| November 05, 2026 | 76.38M |
| November 04, 2026 | 101.64M |
| November 03, 2026 | 96.46M |
| November 02, 2026 | 84.15M |
| October 30, 2026 | 100.67M |
| October 29, 2026 | 118.48M |
| October 28, 2026 | 116.53M |
| October 27, 2026 | 106.17M |
| October 26, 2026 | 98.40M |
| October 23, 2026 | 99.70M |
| October 22, 2026 | 104.88M |
| October 21, 2026 | 100.34M |
| October 20, 2026 | 99.70M |
| October 19, 2026 | 95.16M |
| October 16, 2026 | 90.63M |
| October 15, 2026 | 93.87M |
| October 14, 2026 | 79.62M |
| Date | Value |
|---|---|
| October 13, 2026 | 88.69M |
| October 12, 2026 | 108.12M |
| October 09, 2026 | 113.30M |
| October 08, 2026 | 100.34M |
| October 07, 2026 | 108.12M |
| October 06, 2026 | 106.17M |
| October 05, 2026 | 119.77M |
| October 02, 2026 | 121.72M |
| October 01, 2026 | 119.12M |
| September 30, 2026 | 123.33M |
| September 29, 2026 | 120.93M |
| September 28, 2026 | 122.87M |
| September 25, 2026 | 129.99M |
| September 24, 2026 | 134.52M |
| September 23, 2026 | 137.11M |
| September 22, 2026 | 151.99M |
| September 21, 2026 | 140.99M |
| September 18, 2026 | 143.58M |
| September 17, 2026 | 142.28M |
| September 16, 2026 | 141.64M |
| September 15, 2026 | 140.99M |
| September 14, 2026 | 133.87M |
| September 11, 2026 | 129.99M |
| September 10, 2026 | 149.40M |
| September 09, 2026 | 151.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
| Savara, Inc. | 821.52M |
| Arrowhead Pharmaceuticals, Inc. | 6.282B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.19M |
| Total Expenses (Quarterly) | 24.19M |
| EPS Diluted (Quarterly) | -0.3738 |
| Earnings Yield | -29.42% |
| Normalized Earnings Yield | -29.42 |